title: A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization.
abstract: A randomized, double-blind, placebo-controlled, 4-period crossover study was conducted in 52 healthy adults to assess the effect of delafloxacin on the corrected QT (QTc) interval. The QT interval, corrected for heart rate using Fridericia's formula (QTcF), was determined predose and at 0.5, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 12, 18, and 24 h after dosing with delafloxacin at 300 mg intravenously (i.v.; therapeutic), delafloxacin at 900 mg i.v. (supratherapeutic), moxifloxacin at 400 mg orally (p.o.; positive control), and placebo. The pharmacokinetic profile of delafloxacin was also evaluated. At each time point after delafloxacin administration, the upper limit of the 90% confidence interval (CI) for the placebo-corrected change from the predose baseline in QTcF (ΔΔQTcF) was less than 10 ms (maximum, 3.9 ms at 18 h after dosing), indicating an absence of a clinically meaningful increase in the QTc interval. The lower limit of the 90% CI of ΔΔQTcF for moxifloxacin versus placebo was longer than 5 ms at all 5 time points selected for assay sensitivity analysis, demonstrating that the study was adequately sensitive to assess QTc prolongation. There was no positive relationship between delafloxacin plasma concentrations and ΔΔQTcF. Treatment-emergent adverse events (AEs) were more frequent among subjects receiving a single supratherapeutic dose of 900 mg delafloxacin. There were no deaths, serious AEs, or AEs leading to study discontinuation and no clinically meaningful abnormalities in laboratory values or vital signs observed at any time point after any dose of the study drug.
authors.affiliation: ERT, Philadelphia, Pennsylvania, USA JLitwin@ert.com.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Litwin
authors.affiliation: PPD Inc., Austin, Texas, USA.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Benedict
authors.affiliation: Statistical Resources, Chapel Hill, North Carolina, USA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Thorn
authors.affiliation: Melinta Therapeutics, New Haven, Connecticut, USA.
authors.forename: Laura E
authors.initials: LE
authors.lastname: Lawrence
authors.affiliation: Melinta Therapeutics, New Haven, Connecticut, USA.
authors.forename: Sue K
authors.initials: SK
authors.lastname: Cammarata
authors.affiliation: Melinta Therapeutics, New Haven, Connecticut, USA.
authors.forename: Eugene
authors.initials: E
authors.lastname: Sun
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D024841:Fluoroquinolones / Q000493:pharmacokinetics* / Q000494:pharmacology*; D064368:Healthy Volunteers; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008297:Male; D000077266:Moxifloxacin; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C477891:delafloxacin; D000077266:Moxifloxacin
references.citation: J Antimicrob Chemother. 2000 May;45(5):557-9
references.pmid: 10797074
references.citation: Mol Pharmacol. 2001 Jan;59(1):122-6
references.pmid: 11125032
references.citation: Pharmacotherapy. 2001 Dec;21(12):1468-72
references.pmid: 11765299
references.citation: Pharmacotherapy. 2003 Jul;23(7):881-908
references.pmid: 12885102
references.citation: N Engl J Med. 2004 Mar 4;350(10):1013-22
references.pmid: 14999113
references.citation: J Clin Pharmacol. 2004 May;44(5):464-73
references.pmid: 15102866
references.citation: Antimicrob Agents Chemother. 1999 Jun;43(6):1508-10
references.pmid: 10348784
references.citation: J Antimicrob Chemother. 1999 May;43 Suppl B:83-90
references.pmid: 10382880
references.citation: Ann Noninvasive Electrocardiol. 2006 Jan;11(1):52-6
references.pmid: 16472283
references.citation: J Clin Pharmacol. 2008 Jan;48(1):13-8
references.pmid: 18094216
references.citation: J Antimicrob Chemother. 2012 Dec;67(12):2814-20
references.pmid: 22875850